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ABSTRACT. More than 100 years later after being firstly described, Chagas disease 26	
remains endemic in 21 Latin American countries and has spread to other continents. 27	
Indeed, this disease, caused by the protozoan parasite Trypanosoma cruzi, is no 28	
longer just a problem for the American continent but has become a global health threat. 29	
Current therapies, nifurtimox and benznidazole (Bz), are far from being adequate due 30	
to undesirable effects and their lack of efficacy in the chronic phases of the disease. In 31	
this work, we present an in-depth phenotypical evaluation in T.cruzi of a new class of 32	
imidazole compounds, discovered in a previous phenotypic screening against different 33	
trypanosomatids and designed as potential inhibitors of cAMP phosphodiesterases 34	
(PDEs). The confirmation of several activities similar or superior to Bz prompted a 35	
synthesis program of hit optimization and extended SAR, aimed at improving drug-like 36	
properties such as aqueous solubility, resulting in additional hits with IC50 similar to Bz. 37	
The cellular effects of one representative hit compound 9 (NPD-274), on bloodstream 38	
trypomastigotes were further investigated. Transmission electron microscopy revealed 39	
cellular changes, after just 2 h of incubation with the IC50 concentration, that were 40	
consistent with induced autophagy and osmotic stress - mechanisms previously linked 41	
to cAMP signaling. 9 (NPD-274) induced highly significant increases in both cellular 42	
and medium cAMP, confirming that inhibition of (a) T.cruzi PDE(s) is part of its 43	
mechanism of action. The potent and selective activity of this imidazole-based PDE 44	
inhibitor class against T.cruzi constitutes a successful repurposing of research into 45	
inhibitors of mammalian PDEs. 46	
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INTRODUCTION 50	
Parasites belonging to the order Kinetoplastida are responsible for public health 51	
concerns worldwide and cause extensive human suffering and death. Among these 52	
protozoan flagellates are Trypanosoma brucei spp (T. b. gambiense and T. b. 53	
rhodesiense) and T. cruzi (agents of human African trypanosomiasis and American 54	
trypanosomiasis, respectively), besides various Leishmania spp, which cause 55	
leishmaniasis (1). 56	
American trypanosomiasis, also known as Chagas disease (CD), was described 57	
in 1909 by the Brazilian researcher Carlos Chagas (2). More than 100 years later, this 58	
neglected tropical disease remains endemic in 21 countries from Latin America 59	
according to the WHO (3). Moreover, although the disease was confined to the Region 60	
of the Americas, over the last century, it has spread to other continents mainly due to 61	
human migration (4). 62	
CD is mainly transmitted by blood-sucking reduviid insects in endemic 63	
countries, but other infection routes include vertical transmission, orally via 64	
contaminated beverages and food, blood transfusion and organ transplantation, among 65	
others (2). The disease has an acute phase that occurs immediately after the infection 66	
and is usually asymptomatic/oligosymptomatic. The extent of parasite proliferation is 67	
controlled by a competent host immune response, although the patient remains 68	
chronically infected if untreated. Many of them could remain asymptomatic, but 30-40% 69	
develop a severe stage that is mainly characterized by cardiac and/or gastrointestinal 70	
pathologies (5). Chemotherapy is highly recommended for all acute and chronic 71	
asymptomatic infected patients, but the current drugs, nifurtimox and benznidazole, are 72	
far from adequate due to side effects and their poor efficacy in all clinical phases 73	
(especially inactive against the chronic phase), besides the occurrence of naturally 74	
resistant parasite strains belonging to some different discrete typing units (DTUs) (6).   75	
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For these reasons, the search for effective, well-tolerated and affordable CD 76	
drugs is both urgent and of genuine importance. However, despite significant advances 77	
in the discovery and development of new effective drugs for this tropical disease, it 78	
remains an unmet clinical need (7, 8) and for many patients there is no effective 79	
treatment. This paper describes the therapeutic potential of a class of imidazole 80	
compounds discovered to have anti-protozoan activity in a previous phenotypic 81	
screening against different trypanosomatids of different human PDE inhibitors from our 82	
in-house chemical library (9). Compounds from this chemical class showed potential 83	
utility in Parkinson’s disease due to its ability to inhibit mammalian cyclic nucleotide 84	
PDE10A (10). The work includes an evaluation of the mechanism of action of this 85	
compound class, and initial efforts towards hit optimization and the development of a 86	
structure-activity relationship (SAR). 87	
 88	
RESULTS 89	
Optimization of imidazole hit compounds. A previous phenotypic screen of a 90	
focused library of 69 imidazole derivatives in a panel of three pathogenic 91	
trypanosomatids, T. brucei, T. cruzi and L. infantum, highlighted these imidazoles as 92	
promising hits for the development of anti-Leishmania therapy (9). Interestingly, twelve 93	
members of this library (compounds 1-12) showed also promising activities against the 94	
intracellular forms of T. cruzi (Tulahuen-β-galactosidase-transfected parasites, DTU 95	
VI), some of them being in a quite similar potency as benznidazole (Bz; IC50 = 3.18 µM) 96	
(Table S1 from the Supplemental Material), justifying further analysis of their potential 97	
against T. cruzi, including chemical optimization. 98	
The first priority was to improve the drug-like properties of the compounds with 99	
the most interesting anti-T. cruzi imidazoles. In order to improve aqueous solubility, we 100	
decided to increase the polarity, designing a new serie of imidazole-related compounds 101	
	 5 
with a reduced number of aromatic rings as substituents on the heterocyclic core and 102	
introducing a polar group such as the urea moiety. 103	
The first synthetic approach to obtain these newly designed compounds used 104	
different aminothiazole and aminoimidazole derivatives as starting material, together 105	
with different isocyanates to easily synthesize the corresponding urea in one step, by 106	
microwave irradiation in tetrahydrofuran (THF) with low to moderate yields (Scheme 1). 107	
The second approach was focused on a 4-phenyl-2-amino imidazole scaffold and 108	
employed a two-step synthesis based on the use of 1,1’-carbonyldiimidazole (CDI) as 109	
reagent to convert the amino group into urea. After addition of CDI to the 110	
aminoimidazole, the amine is activated and a carbonyl group added. The addition of 111	
the corresponding substituted amine then allowed the formation of the final urea 112	
derivative with moderate yields (Scheme 2). 113	
Thus, 26 new imidazole-related compounds bearing a urea motif were synthesized and 114	
evaluated against the standard panel (9) of T. brucei, T. cruzi and L. infantum, and their 115	
cytotoxicity evaluated on human lung fibroblast (MRC-5) and primary cultures of 116	
peritoneal mouse macrophages (PMM) (Table 1). Among the new synthesized 117	
compounds, thiazole derivatives (13-17) were not active at all, while the most 118	
promising compounds (23 (NPD-3032), 31 (NPD-3126), 33 (NPD-3024), 37 (NPD-119	
3124) and 38 (NPD-3125)) against intracellular β-galactosidase-transfected T. cruzi 120	
(Tulahuen- strain, DTU VI) were imidazole derivatives bearing a urea motif in position 121	
2. Remarkably, fluoride substituents look like to be favorable for the activity against T. 122	
cruzi (trifluoromethyl at position 4 of R2 substituent in 33, 37 and 38; trifluoromethoxy at 123	
position 4 of one of the phenyl substituents in 23). Moreover, the activity of most of 124	
these compounds was specific to T. cruzi, although some activity was observed against 125	
the other trypanosomatids as well, particularly against the closely related T. brucei; 126	
crucially they displayed little or no toxicity to the mammalian cell lines. The fact that the 127	
introduction of the polar urea group was well tolerated and in some cases actually 128	
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enhanced the selective anti-T. cruzi activity is very encouraging for further exploration 129	
in this chemical space. 130	
[Here, Schemes 1 and 2] 131	
 132	
[Here, Table 1] 133	
 134	
Activity against bloodstream trypomastigotes. In order to verify the 135	
therapeutic potential of this new compound class, we phenotypically assayed the 136	
original imidazole hits (1-12) (Table S1) and the most promising of the new 4-phenyl, 2-137	
ureaimidazoles 23, 31, 33, 37 and 38 (i.e. all the derivatives with an IC50 below 10 µM) 138	
against the other parasite form relevant for the mammalian infection (bloodstream 139	
trypomastigotes – BT). To address the possibility that the compounds might not be 140	
effective against other T. cruzi DTUs, we assayed also another strain from a different 141	
DTU (Y strain - DTU II) for this assay. We found that 5 of the 17 compounds tested 142	
showed greater activity than Bz (IC50 = 12.9 ± 1.9 µM) against Y strain BT, with IC50 143	
values ranging 1.2 - 11.5 µM (Table 2). Compound 9 (NPD-274) stood out as the most 144	
active against this life-cycle stage (IC50 = 1.2 ± 0.3 µM). As heart muscle is an 145	
important target for T. cruzi infection and inflammation, we also investigated the 146	
potential toxicity of these compounds towards primary cultures of mouse cardiac cells. 147	
As shown in Table 2, most compounds were not cardiotoxic, exhibiting LC50 values 148	
ranging from 65 up to > 200 µM. The selective index was calculated, showing 9 (NPD-149	
274) to be the most selective (SI > 85) followed by 33 (NPD-3024) (IC50 = 4.6 ± 0.1 µM, 150	
SI > 44). 151	
 152	
[Here, Table 2] 153	
 154	
Cellular effects of 9 (NPD-274). Imidazole 9 (NPD-274) was chosen for further 155	
analysis of the cellular effects of the imidazole compound class. Bloodstream 156	
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trypomastigotes of Y strain were incubated for 2 h with 1×EC50 of 9 (NPD-274) and the 157	
effects on their ultrastructure were analysed using transmission electron microscopy 158	
(Figure 1). Treated parasites exhibited severe features that included flagellar pocket 159	
dilatation, disruption of Golgi apparatus, extensive blebs and shedding events of the 160	
plasma membrane, in addition to a large number of myelin figures and membranous 161	
profiles surrounding cytoplasmic organelles - an apparent sign of autophagy.  162	
 163	
[Here, Figure 1] 164	
 165	
As related imidazoles were found to be able to increase cAMP levels in Leishmania 166	
promastigote cultures (9), we here tested whether 9 (NPD-274) was similarly able to 167	
increase the levels of this cyclic nucleotide in T. cruzi. With this aim, BT of Y strain 168	
were incubated with either 2× or 5×EC50 of this compound for 2.5 h, and both the 169	
cellular cAMP content and the released cAMP in the medium determined. Cultures 170	
incubated in parallel, either without test compound, or with known T. brucei PDE 171	
inhibitors (NPD-001 (11) and NPD-008 (12)), served as negative and positive controls, 172	
respectively. 173	
Our data demonstrated that incubation with 9 (NPD-274) dose-dependently increased 174	
the intracellular content of cAMP (1.8-fold, P <0.05, and 2.5-fold of untreated control, P 175	
<0.01, at 2× and 5×EC50, respectively) (Figure 2A). cAMP was also released from the 176	
cells and could be measured in the medium; NPD-001, NPD-008 and 9 (NPD-274) all 177	
induced highly significant increases in the extracellular cAMP concentration relative to 178	
the untreated control (P <0.001; Figure 2B).  179	
 180	
[Here, Figure 2] 181	
 182	
DISCUSSION 183	
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Today, Chagas disease is no longer only a problem for Latin America but has become 184	
a global public health threat. Current therapeutic options rely on only two (related: 185	
nitrofuran or nitroimidazole) drugs, nifurtimox and benznidazole, that although active in 186	
the acute phase of the disease, suffer from a significant decrease of efficacy in the 187	
later, chronic stage. Moreover, it has been found that some clinical isolates have 188	
acquired resistance to the nitro-heterocyclic compounds, and that other strains are 189	
innately resistant to these drugs (13). This unsatisfactory situation has led to a 190	
sustained effort including clinical trials with posaconazole, E1224, and fexinidazole (14-191	
16), although today, no new drugs for Chagas disease are on the horizon (6). 192	
Our aim in this work was the study of previously described anti-kinetoplastid hits 193	
bearing an imidazole ring against T. cruzi, including an improvement in their 194	
pharmaceutical profile through increased polarity. From an initial set of 69 imidazole 195	
compounds, 12 derivatives showed promising activities against intracellular T. cruzi 196	
amastigotes, and acceptable selectivity, and thus deserve future studies (Table S1) (9). 197	
However, these imidazoles, all with multiple phenyl substitutions, suffer from sub-198	
optimal solubility. With the aim of decreasing their lipophilicity, we developed a 199	
medicinal chemistry strategy that, while retaining the core five-membered ring 200	
(imidazole or thiazole) with different substituents, introduces a polar 2-urea bridge to 201	
the other part of the molecule, which contains either aromatic or aliphatic tails with 202	
different substituents. A series of 26 new imidazoles, closely related to the original hits 203	
but with fewer aromatic rings and containing a urea moiety, were synthesized in one- 204	
(Scheme 1) or two-step procedures (Scheme 2). 205	
The evaluation of the new 26 compounds in a primary in vitro screening against 206	
a standardized panel of T. brucei, T. cruzi, L. Infantum and mammalian cell lines, 207	
showed that five [23 (NPD-3032), 31 (NPD-3126), 33 (NPD-3024), 37 (NPD-3124) and 208	
38 (NPD-3125)] displayed promising effects against intracellular T. cruzi forms (Table 209	
1). These findings motivated advanced studies on T. cruzi with the most potent 210	
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derivatives (IC50 < 10 µM). In a first step, the activity in other form of the parasite 211	
relevant for human infection, the bloodstream trypomastigotes, was evaluated. For this 212	
assay, also another parasite DTU (Y strain belonging to DTU II) was used. From the 17 213	
compounds evaluated (Table 2), five [2 (NPD-260), 8 (NPD-289), 9 (NPD-274), 31 214	
(NPD-3126) and 33 (NPD-3024)] showed better activity than benznidazole against the 215	
bloodstream forms in vitro, and we selected 9 (NPD-274) for preliminary cellular 216	
studies. Electron microscopy data demonstrated that the major and early ultrastructural 217	
insults included flagellar pocket dilatation, disruption of Golgi apparatus, extensive 218	
blebs and shedding events of the plasma membrane. These events might be linked to 219	
defects in osmoregulation - believed to be one of the functions of cAMP signaling in T. 220	
cruzi (17). In addition large number of myelin figures were observed, as well as 221	
membranous enclosures surrounding cytoplasmic organelles that are the 222	
morphological characteristics of autophagy, as reported for other trypanocidal 223	
compounds (18). Autophagy is a process involved in life cycle progression and 224	
differentiation and in Leishmania cAMP signaling has been directly linked to autophagy 225	
and differentiation (19). Similarly, cAMP signaling has been implicated in life cycle 226	
progression and differentiation in T. cruzi (20-22). Thus, our ultrastructural observations 227	
are compatible with the phenyl-substituted imidazoles acting through the inhibition of 228	
cAMP phosphodiesterases (PDEs), as previously shown in Leishmania (9). 229	
Validation measurements of the intracellular and extracellular cAMP content 230	
after incubation BT with 9 (NPD-274) were therefore conducted. These experiments 231	
were conducted with trypomastigotes as it is impossible to separate out the cAMP of 232	
the much bigger host cells from the cAMP inside amastigotes. Lacking an established 233	
positive control for the stimulation of cAMP in T. cruzi, we utilized two well-234	
characterized inhibitors of T. brucei PDE-B1/B2, NPD-001 and NPD-008 (11, 12), 235	
relying on the very high level of structural conservation in PDEs between kinetoplastids 236	
(23, 24). As expected, both compounds induced a clear and highly significant increase 237	
in the cellular cAMP concentration at concentrations of just 2x or 5x their EC50 value. 238	
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Moreover, 9 (NPD-274) similarly induced cAMP increases: 246% of the untreated 239	
control at 5x EC50 after just 2.5 h of incubation and despite a highly significant increase 240	
in cAMP efflux. Interestingly, all three PDE inhibitors also stimulated the efflux of cAMP 241	
from the trypomastigotes, significantly raising the cAMP concentration in the medium 242	
over that of the control (P <0.001). The phenomenon of cAMP efflux has been 243	
described for mammalian cells, where it is mediated by ABC-class transporters (25), 244	
but to the best of our knowledge it has not been reported for protozoan cells, although 245	
we have previously observed it in T. brucei and Leishmania species (26). The 246	
increased efflux from the trypomastigotes clearly shows that this mechanism in part 247	
compensates for the inhibition of phosphodiesterase activities in the cells; however, as 248	
the cellular levels still increase significantly, we propose that the efflux mechanism was 249	
saturated upon treatment with the PDE inhibitors, leading to toxic cAMP levels and cell 250	
death, as previously demonstrated in T. brucei (11, 12).  251	
Our findings demonstrate a promising in vitro activity of a series of phenyl-252	
substituted imidazole derivatives, several being very active against the different 253	
parasite forms and strains, especially 9 (NPD-274), which merits further studies in 254	
order to contribute to the identification of novel therapies for Chagas disease. 255	
 256	
MATERIALS AND METHODS 257	
Compounds studied. Imidazoles 1-12 from Table S1 were prepared following 258	
previously described procedures (10) and have a purity ≥95% by HPLC. Detailed 259	
synthetic procedures and full characterization of compounds 13-38 shown in Scheme 1 260	
and 2 are given in the supplemental material.  261	
In vitro parasite growth inhibition assays. An integrated screening was used to 262	
define the activity profile of the test compounds from Table 2, using standard assay 263	
protocols as previously described (27). A brief description of each model is given. 1/ 264	
Leishmania infantum: amastigotes harvested from the spleen of infected donor 265	
hamsters were used for infection. Murine peritoneal macrophages were obtained after 266	
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intraperitoneal stimulation with 2% starch in water for 24–48 h and plated in 96-well 267	
microplates at 104 cells/well. After adding 105 amastigotes per well and 5 days of 268	
incubation, parasite burdens are microscopically assessed after Giemsa staining; 2/ 269	
Trypanosoma brucei brucei: bloodstream forms of a drug sensitive T. b. brucei strain 270	
are axenically grown in Hirumi-9 medium at 37 ºC under an atmosphere of 5% CO2. 271	
Assays are performed in 96-well tissue culture plates, each well containing 104 272	
parasites. After 4 days of incubation, parasite growth is assessed by adding resazurin 273	
(Sigma: R7017) and fluorimetric reading after 4 h at 37 ºC; 3/ Trypanosoma cruzi: the 274	
nifurtimox-sensitive Tulahuen strain (Lac Z transfected) of T. cruzi is maintained on 275	
MRC-5 cells. Assays are performed in 96-well tissue culture plates, each well 276	
containing the compound dilutions together with 3×103 MRC-5 cells and 3×104 277	
trypomastigotes. After 7 days incubation, colorimetric reading is performed after 278	
addition of chlorophenol red β-D-galactopyranoside (CPRG) (Sigma: 10884308001) as 279	
substrate; 4/ Cytotoxicity: MRC-5 cells are cultured in MEM medium supplemented with 280	
20 mM L-glutamine, 16.5 mM NaHCO3 and 5% fetal calf serum. Assays are performed 281	
at 37ºC and 5% CO2 in 96-well tissue culture plates with confluent monolayers. After 7 282	
days incubation, cell proliferation and viability are assessed after addition of resazurin 283	
and fluorescence reading. 284	
Stock solution of the selected compounds. 20 mM stock solutions of selected 285	
compounds from Tables S1 and 1 were prepared in pure dimethyl sulfoxide (DMSO, 286	
maximum final concentration of 1% in assays). As a reference drug, N-benzyl-2-(2-287	
nitroimidazol-1-yl)acetamide, benznidazole (Bz; Laboratório Farmacêutico do Estado 288	
de Pernambuco, Brazil) was used (28).  289	
Mammalian cells. Primary cardiac cells (CC) cultures were obtained from mice 290	
embryos and plated onto 0.01% gelatin-coated coverslips in 96-well plates (29). PMM 291	
were purified as previously reported (27). 292	
Parasites. Bloodstream trypomastigotes (BT) of Y strain of T. cruzi were obtained by 293	
cardiac puncture of infected Swiss Webster mice, on the parasitemia peak (29, 30).  294	
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Cytotoxicity assays on cardiac cells. Non-infected CC were incubated at 37 °C for 295	
24 h with increasing concentrations of each compound (12.5 up to 200 µM, 1:2 serial 296	
dilution) diluted in supplemented DMEM. CC morphology was evaluated by light 297	
microscopy and cellular viability of the CC was determined by standardized PrestoBlue 298	
test. The results were expressed as the difference in reduction between treated and 299	
non-treated cells according to the manufacturer instructions, and the value of LC50 300	
(minimum concentration that reduces in 50% the cellular viability) was determined by 301	
non-linear regression using a sigmoid curve with a variable slope (31).  302	
Trypanocidal activity. BT of Y strain (5x106/mL) were incubated for 24 h at 37 °C in 303	
RPMI in the presence or absence of 1:3 serial dilutions of the compounds (0.2 - 50 µM) 304	
for determination of parasite death rates through the direct quantification of live 305	
parasites by light microscopy. The IC50 (compound concentration that reduces  the 306	
number of live parasites by 50%) was calculated by non-linear regression (32); 307	
Selectivity index (SI) is expressed as the ratio between LC50 (toxicity for mammalian 308	
cells) and the IC50 (activity upon the parasite). 309	
Transmission Electron Microscopy. Bloodstream trypomastigotes from Y strain (5 × 310	
106 parasites/mL) were treated with 9 (NPD-274) for 2 h at the concentration 311	
corresponding to its 24 h IC50 value. The parasites were fixed with 2.5% glutaraldehyde 312	
in 0.1 M Na-cacodylate buffer (pH 7.2) at room temperature for 40 min, and postfixed 313	
with a solution of 1% OsO4, 0.8% potassium ferricyanide, and 2.5 mM CaCl2 in the 314	
same buffer for 30 min. The samples were washed in PBS, dehydrated in an ascending 315	
acetone series, and embedded in epoxy resin. Ultrathin sections (Leica Ultracut; UCT; 316	
Leica, Vienna, Austria) were stained with 2% uranyl acetate and lead citrate and 317	
examined using an EM10C Zeiss microscope (Oberkochen, Germany) (33). 318	
cAMP measurement. BT of Y strain (15x106 parasites/mL) were treated with 9 (NPD-319	
274) compound in the concentration of 2x and 5x the IC50 for 2.5 h at 37 °C. After the 320	
incubation, the samples were centrifuged at 5000 rpm for 2 min and the supernatant 321	
collected. The pellet was resuspended in 100 µL of HCl 0.1 M and incubated at 4 °C for 322	
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20 min, followed by centrifugation at 12000 rpm for 10 min and collection of the 323	
supernatant. Samples were stored at -80 °C and then analyzed using a cAMP ELISA 324	
kit (Cayman Chemicals, Michigan, USA) accordingly to the manufacturer instructions 325	
(11). Each experiment was performed independently at least 3 times and all samples 326	
were assayed in duplicate. 327	
 328	
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SCHEME LEGENDS 448	
Scheme 1. Synthesis of substituted N-(thiazole-2-yl)urea (13-17) and N-(1H-imidazol-449	
2-yl)urea (18-23) derivatives using isocyanates. 450	
 451	
Scheme 2. Synthesis of substituted N-(1H-imidazol-2-yl)urea derivatives (24-38) using 452	
1,1’-carbonyldiimidazole (CDI). 453	
 454	
FIGURE LEGENDS 455	
Figure 1. Transmission electron microscopy of bloodstream trypomastigotes Y strain 456	
untreated (A) and treated with 9 (NPD-274) for 2 h (B-K). The treated parasites 457	
exhibited important features that included flagellar pocket dilatation (Frame B; asterisk), 458	
disruption of Golgi apparatus (C, F; <>), extensive blebs (E, G, I; arrows) and shedding 459	
events (J, K; double arrow) of the plasma membrane, as well as a large number of 460	
myelin figures (K; double asterisks) and membranous profiles surrounding cytoplasmic 461	
organelles (D, H; arrowhead). 462	
 463	
Figure 2. Intracellular (A) and extracellular (B) cAMP levels after incubation of 464	
bloodstream trypomastigotes with 9 (NPD-274) and positive controls NPD-001 and 465	
NPD-008. All bars represent the average and SEM of three independent experiments, 466	
each conducted in duplicate. 467	
  468	
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Table 1. In vitro antiparasitic activities (IC50-values, µM) of new imidazole derivatives 469	
(13-38). 470	
Compd. MRC-5 T. cruzi L. infantum T. brucei PMM 
13 (NPD-1368) >64.0 50.5 53.5 >64.0 >64.0 
14 (NPD-1369) >64.0 >64.0 57.4 >64.0 >64.0 
15 (NPD-1371) >64.0 >64.0 49.7 >64.0 >64.0 
16 (NPD-1372) >64.0 >64.0 48.2 >64.0 48.0 
17 (NPD-2906) >64.0 >64.0 36.0 >64.0 36.0 
18 (NPD-2903) 19.5 24.5 32.3 32.3 48.0 
19 (NPD-2904) >64.0 >64.0 37.8 >64.0 48.0 
20 (NPD-2905) 20.9 26.0 19.9 8.2 48.0 
21 (NPD-2907) 12.8 26.5 26.5 >64.0 >64.0 
22 (NPD-2908) >64.0 >64.0 32.5 >64.0 32.0 
23 (NPD-3032) >64.0 7.1 11.7 6.8 >64.0 
24 (NPD-3017) >64.0 >64.0 >64.0 >64.0 >64.0 
25 (NPD-3019) >64.0 >64.0 >64.0 >64.0 >64.0 
26 (NPD-3020) >64.0 >64.0 53.5 >64.0 >64.0 
27 (NPD-3021) >64.0 >64.0 53.5 >64.0 >64.0 
28 (NPD-3022) >64.0 >64.0 19.0 >64.0 32.0 
29 (NPD-3023) >64.0 37.0 15.7 1.8 >64.0 
30 (NPD-3121) >64.0 >64.0 35.1 >64.0 45.2 
31 (NPD-3126) 16.9 3.0 30.0 2.1 33.4 
32 (NPD-3018) >64.0 13.5 32.5 >64.0 32.0 
33 (NPD-3024) >64.0 2.2 7.1 6.0 8.0 
34 (NPD-3025) >64.0 54.6 >64.0 >64.0 >64.0 
35 (NPD-3026) >64.0 49.5 >64.0 >64.0 >64.0 
36 (NPD-3122) >64.0 >64.0 49.4 >64.0 54.6 
37 (NPD-3124) >64.0 1.7 29.3 7.1 34.0 
38 (NPD-3125) >64.0 8.1 39.0 19.3 45.2 
IC50 values for inhibition of the growth of T. cruzi, L. infantum, and T. brucei or for cytotoxicity toward 471	
human lung fibroblasts (MRC-5 cells) and primary cell cultures of peritoneal mouse macrophages (PMM); 472	
Each value is the mean of two independent determinations. 473	
  474	
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Table 2. Activity (IC50 µM) of selected imidazole derivatives against bloodstream 475	
trypomastigotes of Y strain, toxicity profile against cardiac cell cultures (LC50 µM) and 476	
respective selectivity indexes (SI) after 24 h of incubation. Results (IC50 values) are 477	
presented as Mean ± SD.  478	
Comp. Bloodstream 
trypomastigotes 
Y strain (24 h) 
Cardiac cell 
cultures 
SI 
 
1 (NPD-238) >50 >200 ND 
2 (NPD-260) 11.5 ± 0.2 >200 >17 
3 (NPD-311) >50 >200 ND 
4 (NPD-306) 29.7 ± 7.3 >200 >7 
5 (NPD-299) 27.4 ± 4.7 >200 >7 
6 (NPD-301) 16.8 ± 2.7 >200 >12 
7 (NPD-305) >50 >200 ND 
8 (NPD-289) 11.1 ± 0.2 >200 >18 
9 (NPD-274) 1.2 ± 0.3 >100 >85 
10 (NPD-296) >50 >200 ND 
11 (NPD-297) 35.7 ± 2.2 >200 >6 
12 (NPD-276) 22.1 ± 0 >100 >4 
23 (NPD-3032) 13.9 ± 1.8 65.6 5 
31 (NPD-3126) 4.1 ± 1.8 68.6 17 
33 (NPD-3024) 4.6 ± 0.1 >200 >44 
37 (NPD-3124) >50 >200 ND 
38 (NPD-3125) 15.7 ± 5.8 >200 >13 
Benznidazole 12.9 ± 1.9 >1000 >77 
 479	
 480	
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Scheme 1. Synthesis of substituted N-(thiazole-2-yl)urea (13-17) and N-(1H-imidazol-
2-yl)urea (18-23) derivatives using isocyanates. 
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Scheme 2. Synthesis of substituted N-(1H-imidazol-2-yl)urea derivatives (24-38) using 
1,1’-carbonyldiimidazole (CDI). 
	 	
  
Figure 1. Transmission electron microscopy of bloodstream trypomastigotes Y strain 
untreated (A) and treated with 9 (NPD-274) for 2 h (B-K). The treated parasites 
exhibited important features that included flagellar pocket dilatation (Frame B; 
asterisk), disruption of Golgi apparatus (C, F; <>), extensive blebs (E, G, I; arrows) and 
shedding events (J, K; double arrow) of the plasma membrane, as well as a large 
number of myelin figures (K; double asterisks) and membranous profiles surrounding 
cytoplasmic organelles (D, H; arrowhead).  
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Figure 2. Intracellular (A) and extracellular (B) cAMP levels after incubation of 
bloodstream trypomastigotes with 9 (NPD-274) and positive controls NPD-001 and 
NPD-008. All bars represent the average and SEM of three independent experiments, 
each conducted in duplicate. 
	
